The developmental journey of therapies targeting purine receptors: from basic science to clinical trials

[摘要] Since the discovery of ATP as an extracellular signalling molecule in 1972, purinergic signalling, mediated by extracellular purines and pyrimidines has been identified in virtually all mammalian tissues and is implicated in regulating fundamental cellular processes. In recent years, there has been an increasing focus on the pathophysiology and potential therapeutic interventions based on purinergic signalling. A vast range of compounds targeting purine receptors are in clinical development, and many more are in preclinical studies, which highlights the fast growth in this research field. As a tribute to Professor Geoffrey Burnstock’s legacy in purinergic signalling, we present here a brief review of compounds targeting purine receptors that are in different stages of clinical trials. The review highlights the 50-year journey from basic research on purinergic receptors to clinical applications of therapies targeting purine receptors.

[学科分类] 分子生物学，细胞生物学和基因

[关键词] Purinergic signalling;Therapies targeting purine receptors;Diquafosol;Prasugrel;P2X receptor;P2Y receptor;Clinical trials